Previous Close | 5.46 |
1-Year Change | -23.42% |
6-Months Change | 12.81% |
3-Months Change | 37.53% |
Moving Avg (50d) | 5.9546 |
Moving Avg (200d) | 5.4867 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 444.4M |
Beta (3-Years) | 1.93 |
Revenue Growth (ttm) | % |
Net Profit Margin (ttm) | 50.65% |
Return On Assets (ttm) | -32.73% |
EPS (ttm) | -0.65 |
PE Ratio (ttm) | -8.4 |
Dividend Yield | % |
Asset Description: | Anavex Life Sciences Corp. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-08-28 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
5.569 | 5.733 | 5.842 | 6.006 | 6.279 | 6.552 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.